TIME · 22 Oct 2026
A Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42%
The treatment is still experimental, but results from Moderna and Merck add scientific support for a vaccine-based approach to treating the cancer.
⬅ Back home
Read full article ➡